Last year, shareholders approved a HUF 68 per-share dividend on 2017 earnings.

When determining the dividend, an adjustment was made for losses deriving from regulatory concerns over a potential link with liver injury through use of Richterʼs uterine fibroid drug Esmya, noted a report on business news site mfor.hu.

The consolidated report submitted to the AGM in accordance with International Financial Reporting Standards (IFRS) reveals that the Richter group posted after-tax profit of HUF 36.193 bln in 2018, with a balance sheet footing of HUF 797.883 bln.